News >

Phase III Vadastuximab Talirine Frontline AML Trial Discontinued

Jason Harris
Published: Tuesday, Jun 20, 2017

Clay Siegall, PhD

Clay Siegall, PhD

Seattle Genetics has stopped the phase III CASCADE trial of frontline vadastuximab talirine (SGN-CD33A) for patients with acute myeloid leukemia following a recommendation from an independent data monitoring committee.

No patients experienced infusion-related reactions, veno-occlusive disease, or significant liver damage, although grade ≥3 liver function test abnormalities were observed in 1 patient. The most commonly reported grade 1/2 nonhematologic AEs were nausea (55%), diarrhea (33%), and constipation (31%).
Erba HP, Levy MY, Vasu S, et al. A phase 1b study of vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed acute myeloid leukemia (AML). Presented at: 58th American Society of Hematology Annual Meeting; San Diego, CA; December 3-6, 2016. Abstract 906.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x